Introduction: Trigeminal nerve space-occupying lesions refer to abnormal tissue growths arising along the trigeminal nerve pathway. Although these lesions account for only 0.2%–1% of intracranial tumors, their distinctive clinical manifestations and anatomically complex location make diagnosis and treatment particularly challenging.

Trigeminal nerve space-occupying lesions refer to abnormal tissue growths arising along the course of the trigeminal nerve. Although these lesions account for only 0.2%–1% of all intracranial tumors, their distinctive clinical features and complex anatomical location pose unique challenges for diagnosis and treatment. As the primary sensory nerve of the face, the trigeminal nerve originates from the brainstem, traverses the cerebellopontine angle, Meckel’s cave, and the cavernous sinus, and ultimately divides into three branches: the ophthalmic (V1), maxillary (V2), and mandibular (V3) nerves. Tumorigenic lesions can occur at any point along this extensive pathway, the most common of which are trigeminal schwannomas and meningiomas. Thanks to advances in modern neuroimaging and microsurgical techniques, the diagnosis and treatment outcomes for trigeminal nerve space-occupying lesions have improved significantly.

1. Types and Pathogenesis of Trigeminal Nerve Lesions

Trigeminal schwannomas originate from Schwann cells of the trigeminal nerve and are predominantly benign, slow-growing tumors. Depending on their anatomical location, trigeminal schwannomas are generally classified into several types: middle cranial fossa type (primarily located within Meckel’s cave), posterior cranial fossa type (originating from the trigeminal nerve root), and dumbbell-shaped type (involving both the middle and posterior cranial fossae). Among these, the middle cranial fossa type is the most common, accounting for approximately 50% of cases, while dumbbell-shaped tumors represent roughly 20%. These tumors are usually encapsulated and well-demarcated from surrounding tissue; however, because of their deep location and frequent adherence to critical vessels and cranial nerves, complete surgical resection can be technically difficult.

Meningiomas represent another common category of lesions in the trigeminal nerve region. Primary meningiomas arising directly within Meckel’s cave are relatively uncommon; more frequently, meningiomas originating from adjacent skull base dura extend into Meckel’s cave secondarily. Tumor growth often leads to compression of the trigeminal nerve, producing characteristic facial sensory disturbances and pain. Notably, lesions in the trigeminal region usually grow slowly and may require years before producing obvious symptoms, which explains why many tumors are already relatively large at the time of diagnosis.

At the molecular level, trigeminal schwannomas are associated with mutations in the NF2 (neurofibromatosis type 2) gene, while meningiomas are commonly linked to loss of tumor suppressor genes on the long arm of chromosome 22. Additional factors such as viral infection and radiation exposure may also contribute to tumorigenesis, although definitive causal relationships remain under investigation.

 2. Clinical Manifestations and Symptom Analysis

The clinical manifestations of trigeminal nerve lesions are diverse and largely depend on tumor size and location. Facial sensory disturbance is the most common symptom, occurring in approximately 65% of patients and typically presenting as numbness or paresthesia. Symptoms often begin in a localized facial region and gradually expand as the tumor enlarges.

Importantly, true trigeminal neuralgia–like attacks are relatively uncommon, occurring in only about 23% of patients. When present, the pain is more commonly characterized as persistent dull pain or electric shock–like discomfort, usually lacking the classic trigger zones seen in primary trigeminal neuralgia and often responding poorly to carbamazepine and related medications

Motor dysfunction is another important manifestation. Involvement of the motor branch of the trigeminal nerve may lead to weakness of the muscles of mastication and, in severe cases, masticatory muscle atrophy. Patients may complain of difficulty chewing, restricted mouth opening, or mandibular deviation. These findings often indicate either a relatively large tumor or one positioned in a location causing significant compression of motor fibers.

Symptoms related to involvement of other cranial nerves may also occur and are frequently complex. Anterior tumor extension compressing the optic nerve may result in visual decline and visual field defects. Lateral extension into the cavernous sinus can produce ophthalmoplegia, ptosis, and proptosis. Large tumors compressing the seventh and eighth cranial nerves may cause facial muscle spasms, peripheral facial paralysis, tinnitus, and hearing loss. Multiple cranial nerve deficits generally suggest advanced tumor size requiring active intervention.

Symptoms of increased intracranial pressure are particularly common in posterior cranial fossa tumors and often appear relatively early. Because the posterior fossa provides limited intracranial space, tumor growth can obstruct cerebrospinal fluid circulation and lead to obstructive hydrocephalus, manifesting as headache, nausea, vomiting, and papilledema. Interestingly, some tumors may reach very large dimensions—reported cases exceeding 9 cm—while producing only mild symptoms, reflecting both slow tumor growth and the compensatory capacity of the brain.

Certain rare lesions deserve special attention. For example, epidermoid cysts in the trigeminal region may remain asymptomatic for prolonged periods because of their soft consistency and slow growth. However, once they envelop the trigeminal nerve, they may produce intractable facial pain. Such cases emphasize that even mild symptoms warrant detailed imaging evaluation.

3. Diagnostic Methods and Evaluation Strategies

Imaging studies constitute the cornerstone of diagnosis for trigeminal nerve lesions. CT scanning clearly demonstrates osseous changes such as petrous apex erosion or destruction and provides important guidance for surgical planning. MRI is superior for soft tissue characterization and allows precise visualization of the relationship between the tumor, trigeminal nerve, brainstem, and adjacent structures.

On MRI, trigeminal schwannomas typically demonstrate hypointensity on T1-weighted imaging and hyperintensity on T2-weighted imaging, with strong enhancement following contrast administration. Meningiomas, by contrast, usually exhibit isointense T1 and T2 signals with homogeneous enhancement and may demonstrate the characteristic “dural tail sign.”

Functional assessment is equally important. Comprehensive neurological examination should include evaluation of facial sensation, masticatory muscle strength, corneal reflexes, and assessment of other cranial nerves. In patients with large tumors, neuropsychological evaluation may also be necessary to assess potential cognitive impairment. These evaluations contribute not only to diagnosis but also to treatment planning and prognostic assessment.

 Differential diagnosis requires consideration of multiple disorders. Primary trigeminal neuralgia usually demonstrates characteristic trigger zones and intermittent attacks without evidence of a mass lesion on imaging. Other cerebellopontine angle tumors, including vestibular schwannomas and epidermoid cysts, must also be differentiated radiographically. Additional considerations include malignant skull base tumors and multiple sclerosis, requiring integration of clinical findings, imaging characteristics, and laboratory studies when necessary.

Histopathological examination remains the diagnostic gold standard. Tissue obtained through surgery or biopsy undergoes histological and immunohistochemical analysis to determine tumor type and grade. For example, schwannomas typically demonstrate S-100 protein positivity, whereas meningiomas commonly express epithelial membrane antigen (EMA). These molecular markers assist not only in diagnosis but also in prognostic evaluation and therapeutic decision-making.

4. Treatment Strategies and Surgical Techniques

Surgical resection remains the primary treatment modality for trigeminal nerve lesions, particularly in symptomatic or progressively enlarging tumors. The surgical approach depends on tumor location, size, and anatomical relationships. Middle cranial fossa tumors may be approached via a subtemporal route, posterior cranial fossa tumors via a retrosigmoid approach, while dumbbell-shaped tumors may require combined approaches or modified orbitozygomatic approaches.

The primary surgical goal is maximal safe tumor resection while preserving critical neurovascular structures, especially the brainstem and basilar artery.

The application of minimally invasive technologies has substantially improved surgical safety and efficacy. Neuronavigation systems assist surgeons in accurately localizing tumor boundaries, while neuroendoscopy provides superior illumination and visualization, particularly for deep-seated lesions. Intraoperative neurophysiological monitoring enables real-time assessment of cranial nerve function and helps reduce neurological injury. The combined use of these technologies has significantly increased the success rate of surgery for large or anatomically complex trigeminal nerve lesions.

Radiotherapy also plays an important role in selected cases. For residual, recurrent, or unresectable tumors, stereotactic radiosurgery such as Gamma Knife Radiosurgery can achieve excellent tumor control. Radiotherapy is especially valuable for small tumors or for elderly patients and those with significant comorbidities. Studies have shown tumor control rates of approximately 85%–90% for trigeminal schwannomas treated with radiosurgery, with relatively low risk of cranial nerve injury.

Comprehensive treatment strategies must be individualized. Small asymptomatic tumors, particularly in elderly patients, may require only periodic observation. For slow-growing benign tumors, subtotal resection combined with postoperative radiotherapy may sometimes be more appropriate than aggressive gross total resection, especially when tumors are densely adherent to critical structures. Clinical decision-making should integrate tumor pathology, patient age, symptom severity, and overall medical condition.

Postoperative management is essential for treatment success. This includes prevention and management of complications such as cerebrospinal fluid leakage, intracranial hemorrhage, and infection; rehabilitation for cranial nerve dysfunction; and regular follow-up with both clinical and imaging evaluation to monitor for recurrence. Effective postoperative management significantly improves long-term prognosis and quality of life.

5. Prognostic Factors and Rehabilitation Management

The prognosis of trigeminal nerve lesions depends on multiple factors. Tumor type is among the most important determinants. Following complete resection of trigeminal schwannoma, the 10-year survival rate exceeds 90%, whereas malignant lesions carry a less favorable prognosis. Extent of resection significantly affects recurrence risk, with Simpson Grade I resection associated with the lowest recurrence rate. Tumor location also influences outcomes, as middle cranial fossa tumors generally have a better prognosis than posterior cranial fossa lesions because of more favorable surgical exposure.

Recovery of neurological function is another critical indicator of treatment efficacy. Most patients experience symptomatic improvement following surgery, although the degree of recovery varies considerably. Longer duration of preoperative neurological deficits is associated with lower likelihood of functional recovery. Early rehabilitation—including physical therapy, occupational therapy, and targeted neurological rehabilitation—can maximize postoperative recovery. Patients with persistent facial sensory or motor dysfunction may require long-term rehabilitation programs.

Long-term follow-up is essential. MRI examinations are generally recommended every 3–6 months during the first postoperative year, with intervals adjusted thereafter based on clinical findings. Follow-up should assess not only imaging results but also neurological function, quality of life, and treatment-related complications. In recurrent cases, repeat surgery, radiotherapy, or multimodal therapy may be considered. Establishing comprehensive longitudinal follow-up records facilitates timely detection and management of delayed complications.

Quality-of-life assessment should be incorporated into routine follow-up. Standardized scales evaluating physical function, emotional well-being, and social functioning are recommended. Studies indicate that postoperative quality-of-life scores generally improve significantly compared with preoperative status, although they may remain below those of healthy individuals. Psychological support and social rehabilitation are equally important components of long-term management.

6. Frequently Asked Questions

What symptoms can trigeminal nerve lesions cause?

The main symptoms include facial sensory disturbances (facial numbness or tingling in approximately 65% of patients), weakness of mastication (when the motor branch is involved), headache (due to increased intracranial pressure or direct tumor compression), and dysfunction of other cranial nerves, such as visual impairment, tinnitus, and facial paralysis. The specific symptom pattern and severity depend on tumor size and anatomical location.

How are trigeminal nerve lesions treated?

The primary treatment options include surgical resection, radiotherapy, and periodic observation. Small asymptomatic tumors may be monitored with regular follow-up imaging, whereas symptomatic or enlarging tumors are generally treated surgically. Residual or recurrent tumors following surgery may be treated with radiotherapy. Treatment strategies should be individualized based on both tumor characteristics and patient condition.

Is surgery for trigeminal nerve lesions difficult?

Yes. Surgical difficulty depends on tumor size, anatomical location, and relationships with surrounding neurovascular structures. The deep skull base location and anatomical complexity significantly increase operative challenges. However, modern microsurgical techniques and neuronavigation systems have greatly improved both surgical safety and success rates. Selection of an experienced neurosurgical team is critically important.

Reference: https://www.incsg.com/sanchaqiaoliu/7264.html